1800-272-662
Shopping Cart 0
countryflagAU
Login

Structure Therapeutics Inc. American Depositary Shares

Healthcare US GPCR

58.03USD
-0.19(0.33%)

Last update at 2026-03-11T18:01:00Z

Day Range

57.3359.54
LowHigh

52 Week Range

25.5775.02
LowHigh

Fundamentals

  • Previous Close 58.22
  • Market Cap1662.97M
  • Volume447391
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-102.45900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -51.30400M -0.03782M -0.01574M
Minority interest 0.00000M - -
Net income -51.32100M -0.03805M -0.01588M
Selling general administrative 16.37M 0.00859M 0.00354M
Selling and marketing expenses - - -
Gross profit - - -
Reconciled depreciation 0.28M 0.00007M 0.00000M
Ebit -52.83800M -0.03770M -15.90600M
Ebitda -52.56100M -0.03762M -0.01591M
Depreciation and amortization 0.28M 0.00007M -
Non operating income net other - - -
Operating income -52.56100M -0.03770M -0.01591M
Other operating expenses 52.56M 0.04M 0.02M
Interest expense -1.53400M 0.00584M 0.00001M
Tax provision 0.02M 0.00023M 0.00014M
Interest income - - -
Net interest income 1.26M -0.00012M 0.00017M
Extraordinary items - - -
Non recurring - - -
Other items - - -
Income tax expense 0.02M 0.00023M 0.00014M
Total revenue 0.00000M 0.00000M 0.00000M
Total operating expenses 52.56M 0.04M 0.02M
Cost of revenue - - -
Total other income expense net 1.26M -0.00012M 0.00017M
Discontinued operations - - -
Net income from continuing ops -51.32100M -0.03805M -0.01588M
Net income applicable to common shares - -43.76500M -16.03900M
Preferred stock and other adjustments - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 482.02M 97.84M 0.11M 0.04M
Intangible assets - - - -
Earning assets - - - -
Other current assets 6.29M 2.25M 1.94M 0.97M
Total liab 29.05M 212.99M 0.18M 0.06M
Total stockholder equity 452.97M -115.14000M -0.06474M -0.02247M
Deferred long term liab - 3.40M 0.10M -
Other current liab 18.20M 6.74M -3.47569M -1.52411M
Common stock 0.01M 0.00100M 0.00000M 0.00000M
Capital stock 0.01M 0.00100M 0.00000M 0.00000M
Retained earnings -206.57204M -116.95200M -0.06474M -0.02295M
Other liab - - - -
Good will - - - -
Other assets 0.00000M 3.46M 0.11M 0.00800M
Cash 129.79M 90.84M 0.11M 0.02M
Cash and equivalents - - - -
Total current liabilities 24.74M 13.01M 0.00866M 0.00304M
Current deferred revenue 0.36M - - -
Net debt -124.33902M -90.58100M -0.10468M -0.01607M
Short term debt 1.44M 0.26M 0.00035M 0.00015M
Short long term debt - - - -
Short long term debt total 5.45M 0.26M 0.00062M 0.00028M
Other stockholder equity 659.00M -131.09400M - 0.00048M
Property plant equipment - 1.29M 1.79M 0.28M
Total current assets 473.61M 93.09M 0.11M 0.04M
Long term investments - - - -
Net tangible assets - -115.14000M -64.73500M -22.46900M
Short term investments 337.53M 64.75M 0.00200M 0.02M
Net receivables - - - -
Long term debt - - - -
Inventory - - - -
Accounts payable 4.74M 6.01M 3.48M 1.53M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income 0.52M -0.11000M - -0.00000M
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.04M 3.46M 0.00011M 0.00001M
Deferred long term asset charges - - - -
Non current assets total 8.41M 4.76M 0.00191M 0.00028M
Capital lease obligations 5.45M 0.26M 0.00062M 0.00028M
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Investments -62.10800M 0.02M -0.02115M
Change to liabilities 2.15M 1.90M 1.02M
Total cashflows from investing activities -62.10800M 17.86M -21.14700M
Net borrowings - - -
Total cash from financing activities 29.01M 0.10M 0.03M
Change to operating activities 0.81M 2.17M -0.07400M
Net income -51.32100M -0.03805M -0.01588M
Change in cash -79.21400M 0.09M -0.00959M
Begin period cash flow 105.31M 0.02M 0.03M
End period cash flow 26.09M 0.11M 0.02M
Total cash from operating activities -46.12000M -0.03216M -0.01428M
Issuance of capital stock 31.50M 0.10M 0.03M
Depreciation 0.28M 0.00007M 0.07M
Other cashflows from investing activities - - -
Dividends paid - - -
Change to inventory - - -
Change to account receivables - - -
Sale purchase of stock - - -
Other cashflows from financing activities 29.01M 0.10M -0.02115M
Change to netincome 1.96M 1.71M 0.62M
Capital expenditures 0.15M 0.00121M 0.00002M
Change receivables - - -
Cash flows other operating - - -
Exchange rate changes - - -
Cash and cash equivalents changes - - -
Change in working capital 2.97M 0.00406M 0.00095M
Stock based compensation 2.51M 0.00149M 0.00057M
Other non cash items -0.55800M 0.00024M 0.00008M
Free cash flow -46.27500M -0.03337M -0.01430M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
GPCR
Structure Therapeutics Inc. American Depositary Shares		 -0.19 0.33% 58.03 - - - 4.04 -13.372
NVO
Novo Nordisk A/S		 0.05 0.13% 38.77 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -7.26 1.45% 491.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.47 0.84% 778.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics Inc. American Depositary Shares

601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Raymond C. Stevens Ph.D. CEO & Director 1964
Dr. Yingli Ma Ph.D. Chief Technology Officer 1974
Dr. Mark A. Bach M.D., Ph.D. Chief Medical Officer 1957
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 1978
Dr. Xichen Lin Ph.D. Chief Scientific Officer 1974
Mr. Tony Peng Senior Vice President of Legal NA
Mr. Bob Gatmaitan Senior Vice President of People NA
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry NA
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology NA
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.